Anticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effects

Oliver Kepp; Laurie Menger; Erika Vacchelli; Sandy Adjemian; Isabelle Martins; Yuting Ma; Abdul Qader Sukkurwala; Mickaël Michaud; Lorenzo Galluzzi; Laurence Zitvogel; Guido Kroemer

doi:10.4161/onci.21684

Anticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effects

Oliver Kepp, Laurie Menger, Erika Vacchelli, Sandy Adjemian, Isabelle Martins, Yuting Ma, Abdul Qader Sukkurwala, Mickaël Michaud, Lorenzo Galluzzi, Laurence Zitvogel, Guido Kroemer

Résultats de recherche: Contribution à un journal › !!Comment/debate

86 Citations (Scopus)

Résumé

Retrospective clinical data indicate that cardiac glycosides (CGs), notably digoxin, prolong the survival of carcinoma patients treated with conventional chemotherapy. CGs are known to influence the immune response at multiple levels. In addition, recent results suggest that CGs trigger the immunogenic demise of cancer cells, an effect that most likely contributes to their clinical anticancer activity.

langue originale	Anglais
Pages (de - à)	1640-1642
Nombre de pages	3
journal	OncoImmunology
Volume	1
Numéro de publication	9
Les DOIs	https://doi.org/10.4161/onci.21684
état	Publié - 1 déc. 2012

Accès au document

10.4161/onci.21684

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{4c81b391ee774c4d95d4b23903f42904,

title = "Anticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effects",

abstract = "Retrospective clinical data indicate that cardiac glycosides (CGs), notably digoxin, prolong the survival of carcinoma patients treated with conventional chemotherapy. CGs are known to influence the immune response at multiple levels. In addition, recent results suggest that CGs trigger the immunogenic demise of cancer cells, an effect that most likely contributes to their clinical anticancer activity.",

keywords = "Calreticulin, Digitoxin, Digoxin, HMGB1, Immunogenic cell death, Na+/K+ ATPase",

author = "Oliver Kepp and Laurie Menger and Erika Vacchelli and Sandy Adjemian and Isabelle Martins and Yuting Ma and Sukkurwala, {Abdul Qader} and Micka{\"e}l Michaud and Lorenzo Galluzzi and Laurence Zitvogel and Guido Kroemer",

year = "2012",

month = dec,

day = "1",

doi = "10.4161/onci.21684",

language = "English",

volume = "1",

pages = "1640--1642",

journal = "OncoImmunology",

issn = "2162-4011",

number = "9",

}

TY - JOUR

T1 - Anticancer activity of cardiac glycosides

T2 - At the frontier between cell-autonomous and immunological effects

AU - Kepp, Oliver

AU - Menger, Laurie

AU - Vacchelli, Erika

AU - Adjemian, Sandy

AU - Martins, Isabelle

AU - Ma, Yuting

AU - Sukkurwala, Abdul Qader

AU - Michaud, Mickaël

AU - Galluzzi, Lorenzo

AU - Zitvogel, Laurence

AU - Kroemer, Guido

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Retrospective clinical data indicate that cardiac glycosides (CGs), notably digoxin, prolong the survival of carcinoma patients treated with conventional chemotherapy. CGs are known to influence the immune response at multiple levels. In addition, recent results suggest that CGs trigger the immunogenic demise of cancer cells, an effect that most likely contributes to their clinical anticancer activity.

AB - Retrospective clinical data indicate that cardiac glycosides (CGs), notably digoxin, prolong the survival of carcinoma patients treated with conventional chemotherapy. CGs are known to influence the immune response at multiple levels. In addition, recent results suggest that CGs trigger the immunogenic demise of cancer cells, an effect that most likely contributes to their clinical anticancer activity.

KW - Calreticulin

KW - Digitoxin

KW - Digoxin

KW - HMGB1

KW - Immunogenic cell death

KW - Na+/K+ ATPase

UR - http://www.scopus.com/inward/record.url?scp=84876131792&partnerID=8YFLogxK

U2 - 10.4161/onci.21684

DO - 10.4161/onci.21684

M3 - Comment/debate

AN - SCOPUS:84876131792

SN - 2162-4011

VL - 1

SP - 1640

EP - 1642

JO - OncoImmunology

JF - OncoImmunology

IS - 9

ER -